Q-omics provides the consensus-scored BMS1P22 profile across patient tissues and cancer cell-line models. BMS1P22 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, BMS1P22 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, BMS1P22 RNA expression shows 12,947 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, HNSC, and THYM as cancer lineages where BMS1P22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BMS1P22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BMS1P22 survival associations across molecular data types. BMS1P22 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BMS1P22 RNA expression–survival associations across cancer types. High BMS1P22 expression shows unfavorable associations in KIRC, UCEC, LIHC, KIRP and LUAD, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for BMS1P22 RNA expression.
This table summarizes BMS1P22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for BMS1P22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BMS1P22 shows higher tumor expression in HNSC, KIRC, BLCA, LUAD, LIHC and STAD. The HNSC box plot shows higher BMS1P22 RNA expression in tumor versus normal tissue (log2 FC = +0.134, t-test p < 0.001).
This table shows molecular features associated with BMS1P22 in patient tissues and cancer cell lines. In patient samples, BMS1P22 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
